Fundraising FoxAdaptin BIO
OTC: APTNCharlotte, US · Founded 2022 · Delaware corporation · 1 known investors
Find your way into Adaptin BIO
Sign up to see every warm intro you have to Adaptin BIO
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Adaptin BIO team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Adapt Biotechnologies develops the BRiTE platform, a bispecific antibody technology designed to treat brain tumors and intracerebral malignancies by activating T cells to target and destroy glioma cells. The platform combines manipulated T cells with bispecific antibodies to deliver targeted therapy to brain tissue.
Founders & leadership
Adaptin BIO was founded in 2022 by Michael J. Roberts.
Board
Investors · 1
How we know: the S-1 prospectus · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$15M disclosed across 2 rounds · 2025
▶$1.9MraisedJun 2026 · 19 investors · BiotechnologyRule 506(b)
- L. Arthur HewittExecutive Officer
- Patrick GallagherDirector
- Michael RobertsExecutive Officer, Director
- J. Nick RiehleDirector
- Anthony ZookDirector
- Timothy ManessExecutive Officer
- Simon PedderExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $1.9M
- Sales commissions
- $229.4K
- Placement agents
- Laidlaw & Company (UK) Ltd.
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$13.1MraisedFeb 2025 · 95 investors · BiotechnologyRule 506(b)
- Timothy ManessExecutive Officer
- Anthony ZookDirector
- J. Nick RiehleDirector
- L. Arthur HewittExecutive Officer
- Michael RobertsExecutive Officer, Director
- Simon PedderExecutive Officer, Director
- Patrick GallagherDirector
- Offering amount
- $23.4M
- Amount sold
- $13.1M
- Sales commissions
- $475.6K
- Placement agents
- Laidlaw & Company (UK) Ltd.
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 3
Companies working in the same space as Adaptin BIO.
Frequently asked questions
- What does Adaptin BIO do?
- Adapt Biotechnologies develops the BRiTE platform, a bispecific antibody technology designed to treat brain tumors and intracerebral malignancies by activating T cells to target and destroy glioma cells. The platform combines manipulated T cells with bispecific antibodies to deliver targeted therapy to brain tissue.
- Who founded Adaptin BIO?
- Adaptin BIO was founded by Michael J. Roberts in 2022.
- Who are Adaptin BIO's investors?
- Adaptin BIO's investors include Lucius Partners.
- How much funding has Adaptin BIO raised?
- Adaptin BIO has disclosed $15M raised across 2 rounds.
- Where is Adaptin BIO headquartered?
- Adaptin BIO is headquartered in Charlotte, US.